(+)-JQ1

Catalog No.S7110

(+)-JQ1 Chemical Structure

Molecular Weight(MW): 456.99

(+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.

Size Price Stock Quantity  
USD 270 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 42 Publications

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Description (+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.
Features (+)-JQ1 is more effective than (-)-JQ1.
Targets
BRD4 (2) [1]
(Cell-free assay)
BRD4 (1) [1]
(Cell-free assay)
33 nM 77 nM
In vitro

(+)-JQ1 enantiomer binds directly into the Kac binding site of BET bromodomains. (+)-JQ1 (500 nM) binds BRD4 competitively with chromatin resulting in differentiation and growth arrest of NMC cells. (+)-JQ1 (500 nM) attenuates rapid proliferation of NMC 797 and Per403 cell lines as demonstrated by reduced Ki67 staining. (+)-JQ1 (500 nM) potently decreases expression of both BRD4 target genes in NMC 797 cells. (+)-JQ1 inhibits cellular viability with IC50 of 4 nM in NMC 11060 cells. [1] (+)-JQ1 results in robust inhibition of MYC expression in MM cell lines. (+)-JQ1 inhibits proliferating of KMS-34 and LR5 with IC50 of 68 nM and 98 nM, respectively. (+)-JQ1 (500 nM)-treated MM.1S cells results in a pronounced decrease in the proportion of cells in S-phase, with a concomitant increase in cells arrested in G0/G1. (+)-JQ1 (500 nM) results in pronounced cellular senescence by beta-galactosidase staining. (+)-JQ1 (800 nM) exposure leads to a significant reduction in cell viability among the majority of CD138+ patient-derived MM samples tested. [2] (+)-JQ1 inhibits growth of LP-1 cells with GI50 of 98 nM. (+)-JQ1 (625 nM) results in an increase in the percentage of LP-1 cells in G0/G1. (+)-JQ1 (500 nM) suppresses the expression of MYC, BRD4 and CDK9 in LP-1 cells. [3] (+)-JQ1 (1 μM) activates HIV transcription in latently infected Jurkat T cells. (+)-JQ1 (50 μM) stimulates predominantly Tat-dependent HIV transcription in both Jurkat and HeLa cells. (+)-JQ1 (5 μM) induces Brd4 dissociation enables Tat to recruit SEC to HIV promoter and induce Pol II CTD phosphorylation and viral transcription in J-Lat A2 cells. JQ1 enables Tat to increase CDK9 T-loop phosphorylation and partially dissociates P-TEFb from 7SK snRNP in Jurkat T cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
K1  M4nqe2NmdGxiVnnhZoltcXS7IFHzd4F6 NXXBZnpMOjVyL{WwNE8yODByIH7N NIfWcZEzPC92OD:3NkBp NUTrVG1OTE2VTx?= M4jaOIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> NGHLdXUzPjdyN{i4NS=>
BCPAP NYDFN44zS2WubDDWbYFjcWyrdImgRZN{[Xl? MorhNlUxNzVyMD:xNFAxKG6P MYiyOE81QC95MjDo MXTEUXNQ M{nadolvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> MWiyOlcxPzh6MR?=
K1  MmOwR4VtdCCFeXPs[UBCe3OjeR?= MmCxNlUxNzVyMD:xNFAxKG6P NGmwc3Y4OiCq NX\FflI1TE2VTx?= Mlf1ZZJz\XO2czDj[YxtKGO7Y3zlJIF1KEdyL1exJJBp[XOn MoPKNlY4ODd6OEG=
BCPAP M3;qNGNmdGxiQ4njcIUhSXO|YYm= MXWyOVAwPTByL{GwNFAhdk1? Mki1O|IhcA>? M3LZOWROW09? M17SVIFzemW|dIOgZ4VtdCCleXPs[UBifCCJMD;HNUBxcGG|ZR?= M1v5Z|I3PzB5OEix
Hep3B MmHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXmxNWdJOC1zMDFOwG0> NECxOpg2KGR? M1zBU2ROW09? M{GwSGlEPTB;MD6wPEDPxE1? M3P4XFI3PTd3MU[3
HCCLM3 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{CwcVAuOTBizszN NYW3SJBGPSCm NYiwfZk2TE2VTx?= MXnJR|UxRTBwMUSg{txO NX[zdVVzOjZ3N{WxOlc>
HuH7 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3lPYxVOC1zMDFOwG0> NW\GXWZ3PSCm M2q4bWROW09? Mnf2TWM2OD1yLkKxJO69VQ>? MXqyOlU4PTF4Nx?=
HepG2 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXWwMVExKM7:TR?= MkDKOUBl NULMPGlPTE2VTx?= NEX3S2tKSzVyPUCuN|Qh|ryP M1;VTlI3PTd3MU[3
SMMC7721 MkfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWGwMVExKM7:TR?= MVW1JIQ> MlzkSG1UVw>? MX\JR|UxRTBwNEGg{txO M1yw[FI3PTd3MU[3
BEL7402 NVqyN4NXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPyNE0yOCEQvF2= MWW1JIQ> M3LPbmROW09? MYXJR|UxRTBwNEeg{txO NELTVpYzPjV5NUG2Oy=>
MHCC97H NHHYTWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUSwMVExKM7:TR?= MXm1JIQ> MYPEUXNQ MYjJR|UxRTBwNEGg{txO MYiyOlU4PTF4Nx?=
Hep3B MljDR4VtdCCFeXPs[UBCe3OjeR?= MWWwMlEwOC53L{KuOUDPxE1? NIX4RWw1QCCq Mmf6SG1UVw>? NXy4boJqdGWjZIOgeI8h[SC|dXLzeIFvfGmjbDDhZ4N2dXWuYYTpc44hd2ZiSFPDJINmdGy|IHnuJJN2[i2JMTDwbIF{\cLi NXvNZ29mOjZ3N{WxOlc>
HCCLM3 MkW3R4VtdCCFeXPs[UBCe3OjeR?= NXXCe2ZLOC5zL{CuOU8zNjVizszN M4PlSlQ5KGh? M2\P[WROW09? NH;nWWlt\WGmczD0c{BiKHO3YoP0ZY51cWGuIHHjZ5VufWyjdHnvckBw\iCKQ1OgZ4VtdHNiaX6gd5VjNUdzIIDoZZNmyqB? NVvxdYFuOjZ3N{WxOlc>
Hep3B MmT4RZBweHSxc3nzJGF{e2G7 MkLSNE4yNzBwNT:yMlUh|ryP M{TVNFQ5KGh? NXjw[oNYTE2VTx?= MlnNZYN1cX[jdHXzJINie3Cjc3WtN{BidmRiY3HzdIF{\S17IHX4dJJme3Orb36gZY5lKGmwZIXj[YQhWEGUUDDjcIVifmGpZTDhd{B4\WyuIHHzJIN6fG:laILvcYUh[yC{ZXzlZZNmKGmwdH:geIhmKGO7dH;wcIF{dSCocn;tJI1qfG:laH;u[JJq[Q>? NHGyeGszPjV5NUG2Oy=>
HCCLM3 NYfsS|FRSXCxcITvd4l{KEG|c3H5 MU[wMlEwOC53L{KuOUDPxE1? NGD6bpc1QCCq NV33Ooc4TE2VTx?= MlnTZYN1cX[jdHXzJINie3Cjc3WtN{BidmRiY3HzdIF{\S17IHX4dJJme3Orb36gZY5lKGmwZIXj[YQhWEGUUDDjcIVifmGpZTDhd{B4\WyuIHHzJIN6fG:laILvcYUh[yC{ZXzlZZNmKGmwdH:geIhmKGO7dH;wcIF{dSCocn;tJI1qfG:laH;u[JJq[Q>? MoHTNlY2PzVzNke=
A549 NE[0fnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTjepMxNjFvMUCg{txO Mk\hO|IhcA>? MX7pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NUHwXo82OjZ2MUWyNlU>
H157 NEDhN2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVKwMlEuOTBizszN MXe3NkBp NY\kW5F3cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MYGyOlQyPTJ{NR?=
H1299 NIOxTHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkL3NE4yNTFyIN88US=> NEDXUY04OiCq Mn3EbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MnvJNlY1OTV{MkW=
A549 NHXo[YlHfW6ldHnvckBCe3OjeR?= MoPKNU8zNjVxNTFOwG0> NEfw[XEyOiCq M1OycOKhf2Wja3z5JIRm[3KnYYPl[EBD[2xvMjDs[ZZmdHN? M1rUVlI3PDF3MkK1
H1299 NGS0RnZHfW6ldHnvckBCe3OjeR?= MkO5NU8zNjVxNTFOwG0> NWDPVnNIOTJiaB?= NFLGZ3rDqHenYXvsfUBl\WO{ZXHz[YQhSmOuLUKgcIV3\Wy| NEDCZWUzPjRzNUKyOS=>
H157 NHf0b|NHfW6ldHnvckBCe3OjeR?= MkW5NU8zNjVxNTFOwG0> Mn3ZNVIhcA>? NGnKSYRl\WO{ZXHz[YQhTFJ2IHX4dJJme3Orb36= NXnjPWtmOjZ2MUWyNlU>
H1299 MU\GeY5kfGmxbjDBd5NigQ>? NXPEW3htOS9{LkWvOUDPxE1? NXjsSZppOTJiaB?= MUnk[YNz\WG|ZXSgSHI1KGW6cILld5Nqd25? MW[yOlQyPTJ{NR?=
C8161 Ml[2R4VtdCCYaXHibYxqfHliQYPzZZk> NF\FOnUxNTJizszN NFLPOYc1KGR? NVOyPIRuTE2VTx?= MV3k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MUCyOlM6PzJ{Mx?=
Mel285 M2S3NWNmdGxiVnnhZoltcXS7IFHzd4F6 MYmwMVIh|ryP NFLXenQ1KGR? MVTEUXNQ M2PZVYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NXLnUnA{OjZ|OUeyNlM>
Mel290 Mo\XR4VtdCCYaXHibYxqfHliQYPzZZk> NF\WWpkxNTJizszN NYfCW4VUPCCm MlrLSG1UVw>? NETYbWtl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NF7i[oszPjN7N{KyNy=>
92.1 MWHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MnHSNE0zKM7:TR?= NYL0WoFGPCCm MYTEUXNQ MoDZ[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MoL4NlY{QTd{MkO=
Omm1.3 M1:3NWNmdGxiVnnhZoltcXS7IFHzd4F6 M3LaO|AuOiEQvF2= NGXObmI1KGR? NX7idlV6TE2VTx?= NVfLWmlQ\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MXGyOlM6PzJ{Mx?=
Mel202 M4jIdmNmdGxiVnnhZoltcXS7IFHzd4F6 MmLXNE0zKM7:TR?= MY[0JIQ> NUf0c5lGTE2VTx?= NHP6ToFl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M124UVI3Ozl5MkKz
Mel270 Mom2R4VtdCCYaXHibYxqfHliQYPzZZk> NHjrSWYxNTJizszN MmH6OEBl MnuxSG1UVw>? MnTv[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M3LnN|I3Ozl5MkKz
Omm1 MVjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M{jDclAuOiEQvF2= M{LOTlQh\A>? MmDjSG1UVw>? NVPYbmJy\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NGrMb4czPjN7N{KyNy=>
92.1 NW[3cFFISXCxcITvd4l{KEG|c3H5 M1q5N|UxOCCwTR?= NU[zPIdWPDhiaB?= NIi4eGZFVVOR MoLJbY5lfWOnczDhdI9xfG:|aYO= M{nWVVI3Ozl5MkKz
Omm1.3 M4HqS2Fxd3C2b4Ppd{BCe3OjeR?= NYjjXWZIPTByIH7N NVXucXU2PDhiaB?= NV;nTmNNTE2VTx?= MoPubY5lfWOnczDhdI9xfG:|aYO= MYGyOlM6PzJ{Mx?=
92.1 MXPD[YxtKEO7Y3zlJGF{e2G7 NF2y[JE2ODBibl2= M37pVlI1NzR6L{eyJIg> MVrEUXNQ MmDEbY5lfWOnczD0bIUh[2WubDDhZ4N2dXWuYYTpc44h[XRic4XiMWcyyqB? MXuyOlM6PzJ{Mx?=
Omm1.3 NHTxToxE\WyuIFP5Z4xmKEG|c3H5 M4K1b|UxOCCwTR?= NWLJdI9JOjRxNEivO|IhcA>? NX\MOotWTE2VTx?= NGL6OGdqdmS3Y3XzJJRp\SClZXzsJIFk[3WvdXzheIlwdiCjdDDzeYIuTzIEoB?= MYSyOlM6PzJ{Mx?=
A549 NVjRfnppTnWwY4Tpc44hSXO|YYm= MWGxNFAwPDByL{GwNFAhdk1? NILGNFUzPCCq MmL2eZBz\We3bHH0[ZMh[W6mIHHjeIl3[XSnczDTTXJVOQ>? NYHMcJJxOjZ{MUKxPVk>
MCF-7 Ml;MSpVv[3Srb36gRZN{[Xl? MUOxNFAwPDByL{GwNFAhdk1? NIe4eZkzPCCq M3zlPJVxemWpdXzheIV{KGGwZDDhZ5RqfmG2ZYOgV2lTXDF? MVWyOlIyOjF7OR?=
HEK293 MnvMSpVv[3Srb36gRZN{[Xl? NHPycVIyODBxNECwM|ExODBibl2= NIHSemYzPCCq MWn1dJJm\3WuYYTld{BidmRiYXP0bZZifGW|IGPJVnQy M2rXOlI3OjF{MUm5
858 M1X1TWNmdGxiVnnhZoltcXS7IFHzd4F6 NX;kXVBrOC1zIN88US=> Mkj1OUBl MnOxSG1UVw>? NWTBfWVk\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M1nPeFI3OjB4M{Oz
DDR2L63V NUPyTnh4S2WubDDWbYFjcWyrdImgRZN{[Xl? MUSwMVEh|ryP NXXLV2JTPSCm NGG2fZJFVVOR NGfzOWpl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NH;NRlIzPjJyNkOzNy=>
BE(2)-C MoXvR4VtdCCYaXHibYxqfHliQYPzZZk> MXOxJO69VQ>? MWWxMVQh\A>? M3Xz[IRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 MnfJNlYxPjd2NkS=
IMR-32 NIXwS5RE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NWPKclBnOSEQvF2= M{\kUVEuPCCm NXTZdIM5\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? Ml\pNlYxPjd2NkS=
JF MUjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NXTPVWFDOSEQvF2= NUfCb2xuOS12IHS= M{nOS4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 NIH6e5MzPjB4N{S2OC=>
BE(2)-M17 MUXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M37x[FEh|ryP NHztWo0yNTRiZB?= M{\3SoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 MYqyOlA3PzR4NB?=
SK-N-SH M4DyVmNmdGxiVnnhZoltcXS7IFHzd4F6 NHj2S2MyKM7:TR?= MXqxMVQh\A>? NFTiVHVl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? M4e1c|I3ODZ5NE[0
SK-N-DZ  MXXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NYLGR5RQOSEQvF2= MlW1NU01KGR? NUPncml1\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? M1T3VlI3ODZ5NE[0
HMC-1.1  M{\3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPwOU02ODByIH7N NXzC[G1wPDhiaB?= MX;EUXNQ NGPiVlFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MXqyOlA2PTNyMx?=
HMC-1.2 NYPmW4tpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYj0W|REPS13MECwJI5O MUO0PEBp MkTzSG1UVw>? NYXidVVEcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MVSyOlA2PTNyMx?=
ROSA KIT WT  NX\Pcm42T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPVOU02ODByIH7N NFK4RY01QCCq NYPFcpFzTE2VTx?= MUPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M3SyflI3ODV3M{Cz
ROSA KIT D816V MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4f1N|UuPTByMDDuUS=> NXzyfXdkPDhiaB?= NGTCNG1FVVOR MYXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MV6yOlA2PTNyMx?=
HMC-1.1  NHj4TXZCeG:ydH;zbZMhSXO|YYm= M1rrOFIxOC13MECwJI5O M3\v[VQ5KGh? NYDFO29nTE2VTx?= MUTpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NWm0UFg4OjZyNUWzNFM>
HMC-1.2 MnziRZBweHSxc3nzJGF{e2G7 MlPCNlAxNTVyMECgcm0> M4XESlQ5KGh? NIPZdlRFVVOR NInTPYtqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M3[0V|I3ODV3M{Cz
ROSA KIT WT  NES2[4JCeG:ydH;zbZMhSXO|YYm= M2O5dlIxOC13MECwJI5O MlnLOFghcA>? Mkf0SG1UVw>? M1XU[Ilv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MknSNlYxPTV|MEO=
ROSA KIT D816V NFG1VZNCeG:ydH;zbZMhSXO|YYm= MmrCNlAxNTVyMECgcm0> MkLwOFghcA>? NILIfVdFVVOR M3G0VIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NV;adXY1OjZyNUWzNFM>
494H M4PJ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYG3NkBp MUDEUXNQ Mo\JTWM2OD1yLkGyNuKyOC5yMESg{txO M2jsVVI2QTR2NU[2
493H M{nXUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVK3NkBp MkPXSG1UVw>? NWXZU|BsUUN3ME2wMlA1P8LzMD6wNFkh|ryP NXL6UWxxOjV7NES1OlY>
716H M4\4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrwWIc4OiCq NEjSXolFVVOR M4jXUWlEPTB;MD6yNVLDuTBwMEO0JO69VQ>? NX7OVVNZOjV7NES1OlY>
148I Mme2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fNSFczKGh? NX7QR4Q{TE2VTx?= M4nwe2lEPTB;MD6yPFTDuTBwMEO1JO69VQ>? MXSyOVk1PDV4Nh?=
98Sc NFW5ZXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;mO|IhcA>? MXXEUXNQ MY\JR|UxRTBwMUG1xtExNjByNDFOwG0> MXmyOVk1PDV4Nh?=
89R NVvZeWt[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkP1O|IhcA>? MmHCSG1UVw>? MYTJR|UxRTBwMUK2xtExNjByMzFOwG0> NV[5NppYOjV7NES1OlY>
494L MljnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfLO|IhcA>? MVfEUXNQ Ml31TWM2OD1yLkOxO:KyOC5yMUKg{txO MWOyOVk1PDV4Nh?=
493L MlGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2m1Z|czKGh? M4mxSmROW09? NFLN[IpKSzVyPUCuNFUxyrFyLkCxNUDPxE1? MkXBNlU6PDR3Nk[=
148L MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFi5fJY4OiCq MXTEUXNQ Ml;TTWM2OD1yLkG0OuKyOC5yMUeg{txO NW\KUFVVOjV7NES1OlY>
98L NIHMbYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2q3S|czKGh? NX3jN|Z{TE2VTx?= Mn:zTWM2OD1yLkOwPeKyOC5yMkmg{txO M4Tpc|I2QTR2NU[2
OS17 NYjoW3kzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvZfnJNPzJiaB?= NWXmTldSTE2VTx?= MnLaTWM2OD1yLkC3PeKyOC5yMEOg{txO M2Th[|I2QTR2NU[2
OS9 M{DJNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjQUJM4OiCq MlLTSG1UVw>? MXnJR|UxRTBwNEC2xtExNjB{ODFOwG0> MkLCNlU6PDR3Nk[=
MG63 M{fhSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2r0blczKGh? M{DFTWROW09? MmDiTWM2OD1yLkGxOOKyOC5yMkWg{txO Mn7VNlU6PDR3Nk[=
SAOS2 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULQN|BYPzJiaB?= M2TpdmROW09? MkHZTWM2OD1yLkKxO:KyOC5yMEOg{txO NFTvUWczPTl2NEW2Oi=>
U2OS M{\DVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV73WXpHPzJiaB?= MYjEUXNQ NGfxXndKSzVyPUCuNVk5yrFyLkCwPEDPxE1? MUCyOVk1PDV4Nh?=
SJSA-1 NIPFTWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILIbFk4OiCq M3W1O2ROW09? MmLTTWM2OD1yLkGwNOKyOC5yMUCg{txO MUWyOVk1PDV4Nh?=
494H NGLnVJRCeG:ydH;zbZMhSXO|YYm= MY[wMlI2NzBwNT:xMlAh|ryP NXrG[m9mOjRiaB?= NFvFRZJFVVOR MoiybY5kemWjc3XzJIxmfmWuczDv[kBkdGWjdnXkJINie3Cjc3WtN:Kh Mk\0NlU6PDR3Nk[=
148I NI\zdWRCeG:ydH;zbZMhSXO|YYm= NUL4ZWFHOC5{NT:wMlUwOS5yIN88US=> MXuyOEBp MlSwSG1UVw>? NFW5copqdmO{ZXHz[ZMhdGW4ZXzzJI9nKGOuZXH2[YQh[2G|cHHz[U0{yqB? MYOyOVk1PDV4Nh?=
OS17 MlT6RZBweHSxc3nzJGF{e2G7 NGnvOooxNjJ3L{CuOU8yNjBizszN MWCyOEBp M3v2U2ROW09? MV3pcoNz\WG|ZYOgcIV3\Wy|IH;mJINt\WG4ZXSgZ4F{eGG|ZT2zxsA> NFLCTWQzPTl2NEW2Oi=>
494H NFnBZoxCeG:ydH;zbZMhSXO|YYm= M365TlHjiIoQvF2= MVe0PEBp MlL1SG1UVw>? MkW5bY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5 Mmq3NlU6PDR3Nk[=
148I M1\ke2Fxd3C2b4Ppd{BCe3OjeR?= NEjNOJgy6oDLzszN MWK0PEBp NI\WU5hFVVOR NWSzPWdYcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6 MlP4NlU6PDR3Nk[=
OS17 MVvBdI9xfG:|aYOgRZN{[Xl? MVmx5qCK|ryP NYi5e4U2PDhiaB?= NHzoS3hFVVOR MXrpcoR2[2W|IHPlcIwh[XCxcITvd4l{KHOrZ37p[olk[W62bIm= MXuyOVk1PDV4Nh?=
MOLM13 NIXiXm1CeG:ydH;zbZMhSXO|YYm= M4W1VVI2OCCwTR?= MVm0PEBp MVvEUXNQ NHqzWIVqdmS3Y3XzJJNq\26rZnnjZY51dHliYYDvdJRwe2m|IHPveJJm[XSvZX70JJdqfGhicYXpfoFzfGmwaXK= NEnCdZozPTB3M{iyOS=>
MV4-11  MUfBdI9xfG:|aYOgRZN{[Xl? NV[1TmZxOjVyIH7N MnHqOFghcA>? MYTEUXNQ MoXpbY5lfWOnczDzbYdvcW[rY3HueIx6KGGyb4D0c5NqeyClb4Ty[YF1dWWwdDD3bZRpKHG3aYrhdpRqdmmk M1j0WVI2ODV|OEK1
MOLM13 MnzFSpVv[3Srb36gRZN{[Xl? MmTJNlUxKG6P MXGyOEBp NVK0TGhITE2VTx?= M2PGW4VvcGGwY3XzJJF2cXqjcoTpcoljNWmwZIXj[YQhdW:{ZTDwNlEtKEKLTTygZY5lKGOuZXH2[YQhWEGUUB?= MoTSNlUxPTN6MkW=
MV4-11  M2nIfGZ2dmO2aX;uJGF{e2G7 MV2yOVAhdk1? NFLV[VAzPCCq M3jp[mROW09? M4TTd4VvcGGwY3XzJJF2cXqjcoTpcoljNWmwZIXj[YQhdW:{ZTDwNlEtKEKLTTygZY5lKGOuZXH2[YQhWEGUUB?= MmfkNlUxPTN6MkW=
MOLM13 MXvBdI9xfG:|aYOgRZN{[Xl? MmPrNlUxKG6P MnixOFghcA>? NHXIWHBFVVOR Mni2bY5lfWOnczDzbYdvcW[rY3HueIx6KGGyb4D0c5NqeyClb4Ty[YF1dWWwdDD3bZRpKHCxbnH0bY5q[g>? NVzlPFVwOjVyNUO4NlU>
MV4-11  NHH6[3ZCeG:ydH;zbZMhSXO|YYm= MUWyOVAhdk1? NFfSTW81QCCq M{GyTmROW09? NEm4V4NqdmS3Y3XzJJNq\26rZnnjZY51dHliYYDvdJRwe2m|IHPveJJm[XSvZX70JJdqfGhicH;uZZRqdmmk MnjzNlUxPTN6MkW=
Hela MnuwR4VtdCCYaXHibYxqfHliQYPzZZk> NWn0TnA5OC13MECgcm0> M4DR[|czKGh? NHfGPWdFVVOR MYXk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NUjvfJlwOjVyMEmyPVU>
HBL-1 MYfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NUnvcYRqOC13MECgcm0> MX23NkBp MXrEUXNQ Mkn1[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MYCyOVAxQTJ7NR?=
HLY-1 MlrER4VtdCCYaXHibYxqfHliQYPzZZk> MXewMVUxOCCwTR?= MnrsO|IhcA>? NGm0SWZFVVOR NUK1TIpk\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy Mn;5NlUxODl{OUW=
OCI-Ly3 M3KxR2NmdGxiVnnhZoltcXS7IFHzd4F6 MYqwMVUxOCCwTR?= NFzpV5I4OiCq NF64e41FVVOR MVXk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NYHacnZ1OjVyMEmyPVU>
OCI-Ly10 M3rLPGNmdGxiVnnhZoltcXS7IFHzd4F6 MXywMVUxOCCwTR?= NGWwRWk4OiCq M4noWWROW09? MkTD[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NX7pXlNlOjVyMEmyPVU>
SU-DHL-4 M{XjPGNmdGxiVnnhZoltcXS7IFHzd4F6 MnzZNE02ODBibl2= NHrxOZc4OiCq NUTuN3p1TE2VTx?= MoS5[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MlfJNlUxODl{OUW=
SU-DHL-5 MkPUR4VtdCCYaXHibYxqfHliQYPzZZk> NWL3TZBXOC13MECgcm0> MWK3NkBp NFe2bIRFVVOR MWDk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MmfjNlUxODl{OUW=
SU-DHL-6 NH3jd3dE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NHfhR5UxNTVyMDDuUS=> MXe3NkBp MlnwSG1UVw>? NXzYWpRP\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NUDzPWZiOjVyMEmyPVU>
SU-DHL-10 NXvBZphiS2WubDDWbYFjcWyrdImgRZN{[Xl? NV25eGlLOC13MECgcm0> MUK3NkBp MlLySG1UVw>? MYnk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MVqyOVAxQTJ7NR?=
RC-K8 M1HFWWNmdGxiVnnhZoltcXS7IFHzd4F6 NWTrcW1LOC13MECgcm0> M4ryOVczKGh? M1XNNGROW09? M2ToNYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NFjleXMzPTByOUK5OS=>
OCI-Ly8 MlzBR4VtdCCYaXHibYxqfHliQYPzZZk> NX7pOW97OC13MECgcm0> MVy3NkBp MoXuSG1UVw>? MV;k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Mn3INlUxODl{OUW=
OCL-Ly18 MYXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3\IW|AuPTByIH7N NEKxWpM4OiCq MWTEUXNQ M330UoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NXTufmx[OjVyMEmyPVU>
OCI-Ly3 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYD4e4JsOTd{L{K1NE82ODBibl2= MWqyM|ch\A>? Ml\aSG1UVw>? NEO3empqdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0JIF1KHO3Yj3HNUB4cXSqIH3pcolu[WxiY3XscEBl\WG2aNMg M3TUbVI2ODB7Mkm1
OCI-Ly8 NGHKeY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\Ne|E4Oi9{NUCvOVAxKG6P M2jW[FIwPyCm MYjEUXNQ MVrpcoR2[2W|IHPlcIwu[3mlbHWgZZJz\XO2IHH0JJN2[i2JMTD3bZRpKG2rbnntZYwh[2WubDDk[YF1cMLi NXTDcnFDOjVyMEmyPVU>
SU-DHL-4 M3jUN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jlXlE4Oi9{NUCvOVAxKG6P M1f1eVIwPyCm M2fsPGROW09? MX;pcoR2[2W|IHPlcIwu[3mlbHWgZZJz\XO2IHH0JJN2[i2JMTD3bZRpKG2rbnntZYwh[2WubDDk[YF1cMLi MWGyOVAxQTJ7NR?=
SU-DHL-10 NHz5[2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXiZWsyPzJxMkWwM|UxOCCwTR?= NFjwVWQzNzdiZB?= Mm\3SG1UVw>? M2Doe4lv\HWlZYOgZ4VtdC2leXPs[UBienKnc4SgZZQhe3WkLVexJJdqfGhibXnubY1idCClZXzsJIRm[XSqwrC= NUDzVnpWOjVyMEmyPVU>
OCI-Ly3 M2XpfWFxd3C2b4Ppd{BCe3OjeR?= MmHUNVczNzJ3MDDuUS=> M{K4VVdl M1z3XWROW09? MY\pcoNz\WG|ZYOgZ4F{eGG|ZT2zM|ch[WO2aY\peJnDqHOrZ37p[olk[W62bIm= M3\uVVI2ODB7Mkm1
OCI-Ly8 MWrBdI9xfG:|aYOgRZN{[Xl? M4fxZ|E4Oi9{NUCgcm0> MmjQO4Q> NXvWfY86TE2VTx?= MYLpcoNz\WG|ZYOgZ4F{eGG|ZT2zM|ch[WO2aY\peJnDqHOrZ37p[olk[W62bIm= M1rxc|I2ODB7Mkm1
SU-DHL-4 M2ryZ2Fxd3C2b4Ppd{BCe3OjeR?= NYLQd5ZmOTd{L{K1NEBvVQ>? MYq3[C=> NUTPNmFSTE2VTx?= NWW3VnZwcW6lcnXhd4V{KGOjc4Dhd4UuOy95IHHjeIl3cXS7wrDzbYdvcW[rY3HueIx6 NF7DWJkzPTByOUK5OS=>
SU-DHL-10 Ml;iRZBweHSxc3nzJGF{e2G7 MVWxO|IwOjVyIH7N MYi3[C=> M{TZbGROW09? M3fIT4lv[3KnYYPld{Bk[XOyYYPlMVMwPyCjY4Tpeol1gcLic3nncolncWOjboTsfS=> MmDYNlUxODl{OUW=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pDNA-PKcs / γH2AX / Ub-γH2AX / p-c-Jun S63 / Bax; 

PubMed: 26119999     


The comparative effects of the active (+)-JQ1 vs. the inactive (−)-JQ1 on the cellular responsiveness to radiation and the cell fate decision. 

c-Myc; 

PubMed: 23792448     


PEL and non-PEL (Namalwa) cells treated with indicated doses of (+)-JQ1 for 48 hours were lysed and analyzed by Western blot for the expression of c-Myc. GAPDH was used as a loading control. 

p27; 

PubMed: 23792448     


Western blot analysis showing induction of p27 upon 48 hours of treatment with (+)-JQ1. GAPDH serves as a loading control.

26119999 23792448
Growth inhibition assay
Cell viability; 

PubMed: 23792448     


PEL cell lines (BC1, BC3, BCBL1 and JSC1) were treated with indicated doses of (-)-JQ1 or (+)-JQ1 for 5 days and cell viability measured using an MTS assay (refer to Materials and methods). Namalwa, a Burkitt's lymphoma cell line, was used as a control. 

23792448
Immunofluorescence
GM130; 

PubMed: 29074567     


Representative images of A549cells treated with single compounds or in combination (as indicated) are shown. 

MHC / EdU; 

PubMed: 28733670     


C2C12 cultures were switched to DM and treated with 1 µM (+)-JQ1, (−)-JQ1, DMSO or untreated (DM only). Cells were fixed at 12, 24, 48 and 72 hours after treatment and pulsed with EdU 2 hours before fixation. EdU positive nuclei were stained with Alexa Fluor 555 and cultures immunostained for MHC.

29074567 28733670
In vivo (+)-JQ1 (50 mg/kg) inhibits tumors growth in mice with NMC 797 xenografts. (+)-JQ1 (50 mg/kg) results in effacement of NUT nuclear speckles in mice with NMC 797 xenografts, consistent with competitive binding to nuclear chromatin. (+)-JQ1 (50 mg/kg) induces strong (grade 31) keratin expression in NMC 797 xenografts. (+)-JQ1 (50 mg/kg) promotes differentiation, tumor regression and prolonged survival in mice models of NMC xenografts. [1] (+)-JQ1 (50 mg/kg) results in a significant prolongation in overall survival of SCID-beige mice orthotopically xenografted after intravenous injection with MM.1S-luc+ cells compared to vehicle-treated animals. [2] (+)-JQ1 (50 mg/kg i.p.) leads to a highly significant increase in survival of mice bearing Raji xenografts. [3]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: MC 11060 cells
  • Concentrations: ~500 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded into white, 384-well microtiter plates at 500 cells per well in a total volume of 50 μL media. The 797, TT and TE10 cells are grown in DMEM containing 1% penicillin/streptomycin and 10% FBS. The Per403 cells are grown in DMEM containing 1 % penicillin/streptomycin and 20% FBS. Patient-derived NMC 11060 cells are grown in RPMI with 10% FBS and 1% penicillin/streptomycin. (+)-JQ1 is delivered to microtiter assay plates by robotic pin transfer. Following a 48 hours incubation at 37℃, cells are lysed and wells are assessed for total ATP content using a commercial proliferation assay. Replicate measurements are analyzed with respect to dose and estimates of IC50 are calculated by logistic regression (GraphPad Prism).


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Mice bearing NMC 797 xenografts
  • Formulation: 5% DMSO in 5% dextrose
  • Dosages: 50 mg/kg
  • Administration: intraperitoneal injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 91 mg/mL warmed (199.12 mM)
Ethanol 91 mg/mL (199.12 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 456.99
Formula

C23H25ClN4O2S

CAS No. 1268524-70-4
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How can I reconstitute the compound for in vivo injection?

  • Answer:

    JQ1 does not dissolve in water/PBS. The vehicle we recommend is 2% DMSO+30% PEG 300+5% Tween 80+ddH2O. The compound can be dissolved in the vehicle at 5mg/ml and you can use it for IV injection.

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Tags: buy (+)-JQ1 | (+)-JQ1 supplier | purchase (+)-JQ1 | (+)-JQ1 cost | (+)-JQ1 manufacturer | order (+)-JQ1 | (+)-JQ1 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID